Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06134817 · ClinicalTrials.gov registry record · NA
Geniculate Artery Embolization for Treatment of Persistent Knee Pain Post Total Knee Arthroplasty
A NA study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT06134817 is a NA study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 2 participants.
The verdict
NCT06134817, a NA study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
Single-arm, single-center, no sham or placebo, prospective pilot trial designed to evaluate the safety and efficacy of transcatheter arterial embolization in patients with persistent knee pain resistant to conservative management for at least 9 months after total knee arthroplasty (TKA). Eligible participants will receive geniculate artery embolization (GAE) using Embozene™ Color-Advanced Microspheres. Patients will be followed up for a total of 24 months after GAE.
Interventions
- DEVICE Embozene Color-Advanced Microspheres.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-05-24 |
| Est. Completion | 2025-02-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06134817
The ClinicalTrials.gov registry entry for NCT06134817 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Embozene Color-Advanced Microspheres. is the first listed.
NCT06134817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06134817 about?
NCT06134817 is a clinical study titled "Geniculate Artery Embolization for Treatment of Persistent Knee Pain Post Total Knee Arthroplasty". Single-arm, single-center, no sham or placebo, prospective pilot trial designed to evaluate the safety and efficacy of transcatheter arterial embolization in patients with persistent knee pain resistant to conservative management for at least 9 months after total knee arthroplasty (TKA). Eligible pa...
What is the current status of trial NCT06134817?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2024-05-24. Estimated completion is 2025-02-12.
What interventions are being tested in trial NCT06134817?
The interventions under investigation include: Embozene Color-Advanced Microspheres. (DEVICE).
Who is sponsoring clinical trial NCT06134817?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.